

Camillio Porta

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8335732/camillio-porta-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

339
papers

25,610
citations

49
h-index

157
g-index

392
ext. papers

31,428
ext. citations

6.2
avg, IF

6.54
L-index

#	Paper	IF	Citations
339	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089
338	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , 2008 , 372, 449-56	40	2451
337	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1277-1290	59.2	2064
336	Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. <i>Cancer</i> , 2010 , 116, 4256-65	6.4	904
335	Targeting PI3K/Akt/mTOR Signaling in Cancer. <i>Frontiers in Oncology</i> , 2014 , 4, 64	5.3	773
334	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012 , 57, 821-9	13.4	589
333	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019 , 393, 2404-2415	40	490
332	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology, The</i> , 2009 , 10, 757-63	21.7	478
331	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology, The</i> , 2013 , 14, 55-63	21.7	453
330	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1370-1385	21.7	343
329	Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1412-8	2.2	314
328	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 829-841	59.2	280
327	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300	59.2	263
326	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , 2018 , 19, 682-693	21.7	216
325	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 286-96	21.7	215
324	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 2445-2452	12.9	150
323	Receptor activator of NF- κ B (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. <i>PLoS ONE</i> , 2011 , 6, e19234	3.7	136

322	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016 , 15, 83	42.1	129
321	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011 , 47, 1287-98	7.5	118
320	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 1574-1588	21.7	115
319	Store-operated Ca ²⁺ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients. <i>PLoS ONE</i> , 2012 , 7, e42541	3.7	112
318	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011 , 117, 501-9	6.4	110
317	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020 , 5, e001079 ⁶		109
316	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016 , 11, 143-8	5	108
315	Treatment selection in metastatic renal cell carcinoma: expert consensus. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 327-37	19.4	108
314	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. <i>European Urology</i> , 2015 , 67, 100-110	10.2	106
313	Expression pattern of receptor activator of NFB (RANK) in a series of primary solid tumors and related bone metastases. <i>Journal of Cellular Physiology</i> , 2011 , 226, 780-4	7	95
312	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , 2011 , 59, 526-40.2	10.2	89
311	Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. <i>Clinical Cancer Research</i> , 2007 , 13, 5942-51	12.9	81
310	Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. <i>Kidney International</i> , 2010 , 77, 809-15	9.9	78
309	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015 , 11, 354-70	14.9	74
308	SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. <i>Cancer Research</i> , 2005 , 65, 5256-62	10.1	74
307	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
306	Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. <i>Journal of Urology</i> , 2009 , 182, 2569-77	2.5	71
305	Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. <i>Oncology</i> , 2013 , 84, 115-22	3.6	70

304	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology, The</i> , 2020 , 21, 95-104	21.7	70
303	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial 2020 , 8,		68
302	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011 , 108, E250-7	5.6	67
301	Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010 , 46, 2432-40	7.5	62
300	The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002 , 26, 189-93	5.7	62
299	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 283-96	5.6	60
298	Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. <i>Clinical Cancer Research</i> , 2008 , 14, 541-8	12.9	59
297	Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 149-50	3.5	55
296	In vitro antioxidant properties of amifostine (WR-2721, Ethyol). <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 172-6	3.5	54
295	Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. <i>PLoS ONE</i> , 2013 , 8, e83026	3.7	52
294	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016 , 7, 72622-72633	3.3	52
293	Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. <i>European Urology</i> , 2012 , 61, 826-33	10.2	51
292	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
291	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. <i>Anticancer Research</i> , 2013 , 33, 3487-94	2.3	50
290	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
289	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016 , 11, 345-51	5	48
288	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
287	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005 , 48, 429-34	5.9	47

286	Adjuvant low-dose interleukin-2 (IL-2) plus interferon- γ (IFN- γ) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). <i>Journal of Immunotherapy</i> , 2014 , 37, 440-7	5	46
285	5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. <i>Oncology</i> , 1995 , 52, 487-91	3.6	46
284	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016 , 69, 226-235	7.5	45
283	Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. <i>Future Oncology</i> , 2015 , 11, 39-50	3.6	44
282	Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. <i>Current Medicinal Chemistry</i> , 2016 , 23, 3450-3480	4.3	44
281	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
280	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016 , 69, 345-51	10.2	42
279	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010 , 36, 16-23	14.4	42
278	Onco-nephrology: a decalogue. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 515-9	4.3	41
277	Store-operated Ca ²⁺ entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma. <i>BioMed Research International</i> , 2014 , 2014, 739494	3	41
276	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. <i>Cancer Medicine</i> , 2014 , 3, 1517-26	4.8	41
275	Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 774, 17-24	3.2	41
274	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 547-547	2.2	41
273	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. <i>Thorax</i> , 2007 , 62, 690-5	7.3	40
272	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019 , 76, 861-867	10.2	39
271	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. <i>Cancer</i> , 2006 , 107, 2898-905	6.4	39
270	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016 , 11, e0151662	3.7	39
269	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018 , 124, 3677-3683	6.4	38

268	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012 , 110, 692-8	5.6	37
267	Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. <i>Liver International</i> , 2015 , 35, 2001-8	7.9	37
266	Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?. <i>Journal of Cancer</i> , 2011 , 2, 333-8	4.5	37
265	Tolerability of first-line therapy for metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2009 , 35, 297-307	14.4	36
264	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70	3	36
263	New agents in the management of advanced mesothelioma. <i>Seminars in Oncology</i> , 2005 , 32, 336-50	5.5	35
262	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019 , 15, 423-433	14.9	34
261	Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994 , 17, 246-7	2.7	34
260	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1329-1338	4.1	34
259	Glomerular diseases and cancer: evaluation of underlying malignancy. <i>Journal of Nephrology</i> , 2016 , 29, 143-152	4.8	33
258	Understanding the Mechanisms of Resistance in -Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	33
257	Regulation of CD4(+)/NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15 and NKG2D triggering. <i>Cancer Research</i> , 2014 , 74, 68-80	10.1	33
256	Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. <i>The Journal of Supportive Oncology</i> , 2011 , 9, 13-23		33
255	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
254	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 609-609	2.2	32
253	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1571-7	3.5	31
252	Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 1165-1179	11.2	31
251	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014 , 44, 5-16	4.4	30

250	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 601-9	4.4	30
249	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016 , 16, 453	4.8	30
248	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021 , 79, 659-662	10.2	30
247	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 287-294	3.3	29
246	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 82, 323-37	7	29
245	Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. <i>Cancer Immunology, Immunotherapy</i> , 2003 , 52, 359-66	7.4	29
244	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015 , 28, 647-57	4.8	28
243	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. <i>BMC Cancer</i> , 2011 , 11, 105	4.8	28
242	A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. <i>Oncology</i> , 2012 , 82, 333-40	3.6	28
241	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	28
240	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. <i>Therapeutic Advances in Urology</i> , 2017 , 9, 195-207	3.2	27
239	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020 , 77, 449-453	10.2	27
238	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>OncolImmunology</i> , 2020 , 9, 1832348	7.2	27
237	Renin angiotensin system deregulation as renal cancer risk factor. <i>Oncology Letters</i> , 2017 , 14, 5059-5068	2.6	26
236	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) BISCES study, NCT 01064310.. <i>Journal of Clinical Oncology</i> , 2012 , 30, CRA4502-CRA4502	2.2	26
235	Opening an onconeurology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1503-1510	4.3	26
234	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017 , 60, 152-157	14.4	25
233	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019 , 96, 555-567	9.9	25

232	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012 , 48, 2983-92	7.5	25
231	Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. <i>Anticancer Research</i> , 2007 , 27, 165-73	2.3	25
230	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015 , 28, 659-68	4.8	24
229	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020 , 11, 574271	8.4	24
228	Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). <i>European Urology</i> , 2013 , 63, 254-61	10.2	24
227	Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020 , 136, 195-203	7.5	24
226	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018 , 13, 705-714	5	24
225	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). <i>Journal of Nephrology</i> , 2017 , 30, 171-180	4.8	23
224	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019 , 15, 929-941	3.6	23
223	Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. <i>Oncology</i> , 2015 , 88, 273-80	3.6	23
222	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021 , 4, e2021869	10.4	23
221	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015 , 20, 1028-35	5.7	22
220	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015 , 26, 2392-8	10.3	22
219	Endoplasmic Reticulum Ca(2+) Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 2260-71	4.7	22
218	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 132, 89-99	7	22
217	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
216	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 631-643	3.8	21
215	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. <i>Metabolites</i> , 2020 , 10,	5.6	21

214	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020 , 11, 490	8.4	21
213	Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. <i>Scientific World Journal, The</i> , 2007 , 7, 837-49	2.2	21
212	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4512-4512	2.2	21
211	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019 , 24, 338-348	5.7	21
210	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101966	14.4	20
209	Granulocyte dysplasia and dysfunction, and CD11/CD18 defects in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 1996 , 23, 267-75	1.9	20
208	Vitamin K effects in human health: new insights beyond bone and cardiovascular health. <i>Journal of Nephrology</i> , 2020 , 33, 239-249	4.8	20
207	AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer. <i>BJU International</i> , 2019 , 124, 693	5.6	19
206	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 471-6	3.3	19
205	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 553-61	7.4	19
204	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019 , 2, 643-648	6.7	19
203	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 308-308	2.2	19
202	Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. <i>Clinical Therapeutics</i> , 2017 , 39, 567-580.e2	3.5	18
201	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020 , 52, 297-309	1.6	18
200	Sorafenib tosylate in advanced kidney cancer: past, present and future. <i>Anti-Cancer Drugs</i> , 2009 , 20, 409-15	4.5	18
199	Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. <i>Mayo Clinic Proceedings</i> , 1999 , 74, 570-4	6.4	18
198	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 14408-14415	3.3	18
197	Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. <i>Oncology Reports</i> , 2005 , 14, 113-20	3.5	18

196	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019 , 24, 491-497	5.7	17
195	A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. <i>BJU International</i> , 2011 , 107, 1190-9	5.6	17
194	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021 , 6, 100030	6	17
193	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017 , 8, 7328-7335	3.3	16
192	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e903-e908	3.3	16
191	Use of Sorafenib in Two Metastatic Renal Cell Cancer Patients with End-Stage Renal Impairment Undergoing Replacement Hemodialysis. <i>Tumori</i> , 2009 , 95, 542-544	1.7	15
190	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020 , 3, 530-539	6.7	14
189	Acute Kidney Injury in Cancer Patients. <i>Contributions To Nephrology</i> , 2018 , 193, 137-148	1.6	14
188	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014 , 1, 181-188	4	14
187	CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. <i>British Journal of Cancer</i> , 2017 , 117, 947-953	8.7	14
186	Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 155-63	2.7	14
185	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
184	Tivantinib (ARQ197) in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 615-22	3.5	13
183	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. <i>Journal of Cellular Physiology</i> , 2000 , 185, 126-34	7	13
182	Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. <i>World Journal of Hepatology</i> , 2010 , 2, 103-13	3.4	13
181	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019 , 71, 149-163	2.2	13
180	Weekly taxanes in metastatic breast cancer (review). <i>Oncology Reports</i> , 2002 , 9, 1047-52	3.5	13
179	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018 , 24, 447-456	2.6	12

178	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019 , 16, 655-673	5.5	12
177	Allopurinol mouthwashes in methotrexate-induced stomatitis. <i>Arthritis and Rheumatism</i> , 1994 , 37, 777-8		12
176	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020 , 5,	6	12
175	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 50-9	7	11
174	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018 , 70, 112-117	14.4	11
173	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	7	11
172	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014 , 10, 1741-50	3.6	11
171	Thrombotic thrombocytopenic purpura (TTP): Retrospective study of 84 patients and therapeutic prospects. <i>Transfusion Science</i> , 1992 , 13, 39-44		11
170	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e84-e91	3.3	11
169	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211019642	5.4	11
168	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	10
167	Bevacizumab plus interferon- γ versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. <i>Clinical Drug Investigation</i> , 2011 , 31, 507-17	3.2	10
166	The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. <i>Future Oncology</i> , 2012 , 8, 1051-7	3.6	10
165	Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 423-8	3.5	10
164	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 581-581	2.2	10
163	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10
162	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020 , 98, 1108-1119	9.9	10
161	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. <i>Oncolimmunology</i> , 2020 , 9, 1846901	7.2	9

160	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 643-55	4	9
159	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015 , 11, 3159-66	3.6	9
158	Eosinophils and serum eosinophilic cationic proteins in interleukin-2-based immunotherapy for cancer. <i>British Journal of Haematology</i> , 1998 , 100, 607-9	4.5	9
157	Re: damien pouessel, stphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. <i>Eur urol</i> 2008;53:376-81. <i>European Urology</i> , 2008 , 53, 1092-3	10.2	9
156	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017 , 23, 2448-2452	5.6	9
155	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 425-435.e4	3.3	9
154	Preventive strategies for acute kidney injury in cancer patients. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 70-83	4.5	9
153	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 269-269	2.2	9
152	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 227-233	3.5	8
151	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 477-488	3.3	8
150	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 406-414	3.3	8
149	Transplantation of kidneys with tumors. <i>Journal of Nephrology</i> , 2016 , 29, 163-168	4.8	8
148	The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 1113-1124	3.5	8
147	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 262-9	3.3	8
146	Autoimmunity in thrombotic thrombocytopenic purpura. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 633-40	5.3	8
145	The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?. <i>PLoS ONE</i> , 2015 , 10, e0120427	3.7	8
144	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020 , 78, 783-785	10.2	8
143	Large Extracellular Vesicles-A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8

142	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1667-1678	7.4	8
141	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017 , 25, 39-43	1.9	7
140	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 140, 39-51	7	7
139	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 149-157	7	7
138	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2019 , 105, 3-12	1.7	7
137	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. <i>Future Oncology</i> , 2012 , 8, 1605-12	3.6	7
136	Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. <i>Cancers</i> , 2021 , 13,	6.6	7
135	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 139, 143-148	7	7
134	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. <i>Journal of Nephrology</i> , 2019 , 32, 57-64	4.8	7
133	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. <i>Future Oncology</i> , 2018 , 14, 1347-1354	3.6	7
132	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. <i>ESMO Open</i> , 2020 , 5,	6	6
131	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). <i>Kidney Cancer</i> , 2018 , 2, 31-36	0.6	6
130	Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 299-307	3.3	6
129	Considerations for the design of future clinical trials in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 1-12	3.3	6
128	Axitinib dose titration: what's the limiting factor?. <i>Lancet Oncology, The</i> , 2013 , 14, 1152-4	21.7	6
127	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. <i>Cancer Treatment Reviews</i> , 2012 , 38, 127-32	14.4	6
126	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , 2002 , 38, 159-62	5.9	6
125	'TUNEL' evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. <i>British Journal of Haematology</i> , 1999 , 104, 424-5	4.5	6

124	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 564-564	2.2	6
123	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	6
122	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	6
121	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. <i>Future Oncology</i> , 2016 , 12, 533-49	3.6	6
120	Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. <i>Oncology Reports</i> , 2002 , 9, 1107-13	3.5	6
119	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
118	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 205-216	4	5
117	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019 , 42, 1878-1892	3.5	5
116	Renal cell carcinoma treatment after first-line combinations. <i>Lancet Oncology, The</i> , 2019 , 20, 1332-1334	21.7	5
115	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 144, 102812	7	5
114	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017 , 8, 329	5.6	5
113	Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. <i>Tumori</i> , 2015 , 101, 139-43	1.7	5
112	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013 , 9, 831-43	3.6	5
111	Indirect treatment comparison of bevacizumab + interferon- α vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011 , 3, 19-27	1.7	5
110	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1089-96	3.5	5
109	Nitrate plasma level as a marker of nitric oxide production after subcutaneous interleukin 2 immunotherapy. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1545	9.7	5
108	Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2006 , 32, 229-33	14.4	5
107	Effect of different platelet agonists on intracellular free Ca ⁺⁺ concentrations in human tumor cells: possible role in tumor growth. <i>International Journal of Cancer</i> , 1995 , 62, 291-6	7.5	5

106	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021 , 4, 274-281	6.7	5
105	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 2005 , 13, 689-95	3.5	5
104	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	5
103	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 151-162	5.4	4
102	Targeting angiogenesis in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 245-257	3.5	4
101	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	2.8	4
100	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e588-e597	3.3	4
99	Optimizing treatment for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1901-11	3.5	4
98	Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 141-52	3.5	4
97	HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. <i>Cancer Letters</i> , 1995 , 98, 121-125	9.9	4
96	Anti-HCV antibodies and hepatocellular carcinoma. Relationship in a medium-risk population. <i>Upsala Journal of Medical Sciences</i> , 1992 , 97, 261-6	2.8	4
95	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2021 , 81, 266-266	10.2	4
94	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 581130	5.3	4
93	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , 2003 , 11, 161-7	4.4	4
92	Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. <i>BJU International</i> , 2017 , 119, 846-853	5.6	3
91	Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3219-20	2.2	3
90	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. <i>BJU International</i> , 2011 , 107, 747-748	5.6	3
89	Nitrite and Nitrate Plasma Levels, as Markers for Nitric Oxide Synthesis, in Thrombotic Thrombocytopenic Purpura (TTP). <i>Hematology</i> , 1996 , 1, 239-46	2.2	3

88	High-dose human immunoglobulins in thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1994 , 45, 99-100	7.1	3
87	Utility of embolization of chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. <i>Cancer</i> , 1995 , 75, 2782-4	6.4	3
86	Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4575-4575	2.2	3
85	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 642-642	2.2	3
84	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020 , 98, 1407-1418	9.9	3
83	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021 , 13,	6.6	3
82	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. <i>Genes</i> , 2021 , 12,	4.2	3
81	Uterine carcinosarcoma: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103369	7	3
80	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2429-30	2.2	3
79	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021 , 155, 56-63	7.5	3
78	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. <i>Microvascular Research</i> , 2021 , 138, 104189	3.7	3
77	Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. <i>Tumori</i> , 2009 , 95, 542-4	1.7	3
76	A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. <i>Anticancer Research</i> , 2013 , 33, 4999-5004	2.3	3
75	Immune-based combination therapy for metastatic kidney cancer. <i>Nature Reviews Nephrology</i> , 2019 , 15, 324-325	14.9	2
74	Evidence and experience for the management of metastatic renal cell carcinoma. <i>European Journal of Cancer, Supplement</i> , 2013 , 11, 1-8	1.6	2
73	Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. <i>Immunotherapy</i> , 2011 , 3, 487-90	3.8	2
72	Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 41, 171-2	3.5	2
71	Thrombotic thrombocytopenic purpura and relapses: why do case series differ? The Italian Cooperative Group for TTP. <i>American Journal of Hematology</i> , 1996 , 52, 215-6	7.1	2

70	Autoantibody profile in thrombotic thrombocytopenic purpura. <i>Transfusion Science</i> , 1992 , 13, 33-36		2
69	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5071-5071	2.2	2
68	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. <i>Lancet Oncology, The</i> , 2021 , 22, e532	21.7	2
67	An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. <i>Journal of Medical Economics</i> , 2020 , 23, 1579-1587	2.4	2
66	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 339-339	2.2	2
65	Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. <i>Cancers</i> , 2021 , 13,	6.6	2
64	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 2004 , 12, 855-9	3.5	2
63	Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. <i>Oncology Reports</i> , 2008 , 20, 1511-9	3.5	2
62	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2020 ,	3.9	1
61	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 254-63	7	1
60	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 705-709	2.4	1
59	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era. <i>Urology</i> , 2019 , 122, 100-104	6.7	1
58	Sequential therapy in metastatic renal cell carcinoma: what comes next?. <i>Medical Oncology</i> , 2012 , 29, 1914-5	3.7	1
57	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. <i>Tumori</i> , 2013 , 99, e282-e284	1.7	1
56	Prognostic factors in advanced renal cell cancer. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 35-37	1.6	1
55	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4572-4572 ¹	2.2	1
54	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5062-5062	2.2	1
53	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 484-491	2.8	1

52	Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. <i>Translational Andrology and Urology</i> , 2012 , 1, 120-2	2.3	1
51	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021 , 11, e049128	3	1
50	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302	3.2	1
49	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-9	4.4	1
48	Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus 2017 , 273-294		1
47	Conventional chemotherapy 2020 , 127-153.e11		1
46	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2199-2204	4	1
45	Exploring the Spectrum of Kidney Ciliopathies. <i>Diagnostics</i> , 2020 , 10,	3.8	1
44	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. <i>Cancer Treatment Reviews</i> , 2021 , 94, 102157	14.4	1
43	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome 2019 , 234-250.e1		1
42	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211022870	3.2	1
41	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 313-313	2.2	1
40	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. <i>Journal of Neuroendocrinology</i> , 2021 , 33, e13041	3.8	1
39	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. <i>Cancer Treatment Reviews</i> , 2021 , 100, 102288	14.4	1
38	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).. <i>Radiologia Medica</i> , 2022 , 1	6.5	1
37	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations.. <i>Cancer Treatment Reviews</i> , 2022 , 105, 102379	14.4	1
36	A Glimpse in the Future of Malignant Mesothelioma Treatment.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 809337	5.6	1
35	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. <i>Tumori</i> , 2020 , 300891620915786 ^{1.7}		0

34	Reply to S. Barni et Al and M. Sun et Al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3783-4	2.2	o
33	Renal cell carcinoma and viral infections: A dangerous relationship?. <i>World Journal of Nephrology</i> , 2022 , 11, 1-12	3.6	o
32	Renal Cancer. <i>UNIPA Springer Series</i> , 2021 , 755-774	0.1	o
31	Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors. <i>Cancer Management and Research</i> , 2021 , 13, 7623-7636	3.6	o
30	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. <i>Biologics: Targets and Therapy</i> , 2021 , 15, 441-450	4.4	o
29	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. <i>Current Opinion in Urology</i> , 2021 , 31, 236-241	2.8	o
28	Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. <i>Journal of Bone Oncology</i> , 2021 , 26, 100337	4.5	o
27	TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 278-278	2.2	o
26	Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?. <i>Future Oncology</i> , 2021 , 17, 3579-3584	3.6	o
25	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. <i>Translational Oncology</i> , 2021 , 14, 101153	4.9	o
24	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079580	5.4	o
23	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 727	3.6	o
22	Abemaciclib for malignant pleural mesothelioma. <i>Lancet Oncology, The</i> , 2022 , 23, e237	21.7	o
21	RETRACTION: The biological mechanism involved in anticancer properties of amniotic membrane. <i>Oncology Reviews</i> , 2020 , 14, 493	4.3	
20	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors 2020 , 299-306.e1		
19	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012 , 62, e7-e8	10.2	
18	Predicting efficacy of sunitinib in metastatic renal cell carcinoma. <i>Current Biomarker Findings</i> , 2014 , 43		
17	mRCC management: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 1-11	1.6	

- 16 Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction. *Urologia*, **2011**, 78 Suppl 18, 9-15 1.2
- 15 Nephrectomy as a component of systemic treatment for renal cell carcinoma patients. *Journal of Surgical Oncology*, **1994**, 56, 81-2 2.8
- 14 New Target Therapies for Malignant Mesothelioma **2005**, 765-777
- 13 Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. *American Journal of Translational Research (discontinued)*, **2021**, 13, 8598-8610 3
- 12 First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. *World Journal of Clinical Oncology*, **2021**, 12, 1037-1046 2.5
- 11 Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. *Journal of Clinical Oncology*, **2019**, 37, e14054-e14054 2.2
- 10 A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. *Journal of Clinical Oncology*, **2019**, 37, e16109-e16109 2.2
- 9 Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. *Journal of Clinical Oncology*, **2020**, 38, 632-632 2.2
- 8 Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. *Journal of Clinical Oncology*, **2020**, 38, 5070-5070 2.2
- 7 Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies **2015**, 555-575
- 6 Combination therapy & future directions in RCC **2011**, 126-142
- 5 The basics of onco-nephrology in the renal clinic. *Journal of Nephrology*, **2020**, 33, 1143-1149 4.8
- 4 Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. *Journal of Onco-Nephrology*, **2020**, 4, 153-164 0.2
- 3 Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. *Kidney Cancer*, **2021**, 5, 93-106 0.6
- 2 Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. *Global & Regional Health Technology Assessment*, **2018**, 2018, 228424031879073 0.2
- 1 Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The Etry study from the Italian Group of Onco-Nephrology (G.I.O.N.). *Journal of Onco-Nephrology*, 239936932210936 0.2